Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
DOI:
https://doi.org/10.2340/00015555-3678Keywords:
psoriasis, anti-interleukin 17, elderly, safety, drug survivalAbstract
Anti-interleukin-17 agents have recently been developed for the treatment of psoriasis. This study evalu?ated the tolerance and effectiveness of anti-interleukin-17 agents for psoriasis in elderly patients in daily practice. A multicentre, retrospective study was performed, involving psoriatic patients aged ?65 years who had received an anti-interleukin-17 agent, including secukinumab, ixekizumab or brodalumab. A total of 114 patients were included: 72 received secukinumab, 35 ixekizumab, and 7 brodalumab. Treatment was stopped in 32 patients (28.9%), because of relapses in 14 patients (41.2%), primary failures in 11 patients (32.4%), or adverse events in 7 patients (20.6%). The 3 most frequently reported adverse events were injection site reactions (n?=?4), oral candidiasis (n?=?3), and influenza-like illness (n?=?3). Regarding effectiveness, 80 patients (70%) reached a Physician Global Assessment score of 0/1, 6 months after treatment initiation. In conclusion, anti-interleukin-17 therapy appears to be an effective and safe therapeutic option for psoriasis treatment in patients aged ??65 years.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Céline Phan, Nathalie Beneton, Juliette Delaunay, Ziad Reguiai, Claire Boulard, Anne-Claire Fougerousse, Elisa Cinotti, Marco Romanelli, Laure Mery-Bossard, Domitille Thomas-Beaulieu, Josiane Parier, François Maccari, Jean-Luc Perrot, Mireille Ruer-Mulard, Marie Bastien, Edouard Begon, Mahtab Samimi, Caroline Jacobzone, Nathalie Quiles-Tsimaratos, Vincent Descamps, Maud Steff, Paul Bilan, Annie Vermersch-Langlin, Mathilde Kemula, Emmanuelle Amazan, Ingrid Kupfer-Bessaguet, Anne-Caroline Cottencin, Francesca Prignano, Bulai Livideanu, Jeremy Gottlieb, Alain Beauchet, Mahé, Emmanuel for the Groupe dEtudes Multicentriques (GEM) RESOPSO
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
